Do analysts prefer MIRA or TNYA?

Tenaya Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 408.32%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tenaya Therapeutics is more favorable than MIRA Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Tenaya Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Which has preferable valuation & earnings, MIRA or TNYA?

Tenaya Therapeutics is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MIRA Pharmaceuticals N/A N/A -$10.44M -$1.30 N/A Tenaya Therapeutics N/A N/A -$90.60M -$0.47 N/A

Is MIRA or TNYA more profitable?

Tenaya Therapeutics' return on equity of -80.56% beat MIRA Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets MIRA Pharmaceuticals N/A -140.82% -135.01% Tenaya Therapeutics N/A -80.56% -65.21%

Do analysts prefer MIRA or CRBP?

Corbus Pharmaceuticals has a consensus price target of $40.67, suggesting a potential upside of 339.64%. Given Corbus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than MIRA Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Corbus Pharmaceuticals 2 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has preferable earnings and valuation, MIRA or CRBP?

Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MIRA Pharmaceuticals N/A N/A -$10.44M -$1.30 N/A Corbus Pharmaceuticals N/A N/A -$78.54M -$5.82 N/A

Is MIRA or CRBP more profitable?

Corbus Pharmaceuticals' return on equity of -70.89% beat MIRA Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets MIRA Pharmaceuticals N/A -140.82% -135.01% Corbus Pharmaceuticals N/A -70.89% -61.78%

Do analysts prefer MOLN or MIRA?

Molecular Partners presently has a consensus target price of $8.38, suggesting a potential upside of 110.43%. Given Molecular Partners' stronger consensus rating and higher probable upside, research analysts plainly believe Molecular Partners is more favorable than MIRA Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Molecular Partners 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is MOLN or MIRA more profitable?

Molecular Partners' return on equity of -66.62% beat MIRA Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Molecular Partners N/A -66.62% -54.85% MIRA Pharmaceuticals N/A -140.82% -135.01%

Do analysts prefer ASRT or MIRA?

Assertio currently has a consensus price target of $22.65, indicating a potential downside of 3.62%. Given Assertio's higher probable upside, analysts plainly believe Assertio is more favorable than MIRA Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Assertio 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80 MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend SPRB or MIRA?

Spruce Biosciences presently has a consensus price target of $163.00, suggesting a potential upside of 210.42%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Spruce Biosciences is more favorable than MIRA Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spruce Biosciences 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.60 MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, SPRB or MIRA?

Spruce Biosciences is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spruce Biosciences N/A N/A -$38.97M -$36.60 N/A MIRA Pharmaceuticals N/A N/A -$10.44M -$1.30 N/A

Is SPRB or MIRA more profitable?

MIRA Pharmaceuticals' return on equity of -140.82% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Spruce Biosciences N/A -155.40% -101.67% MIRA Pharmaceuticals N/A -140.82% -135.01%

MIRA Pharmaceuticals (MIRA) Competitors

$0.94 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$0.96 +0.02 (+1.61%)

As of 07/2/2026 07:56 PM Eastern

Compare

MIRA vs. TNYA, CRBP, MOLN, ASRT, and SPRB

Should you buy MIRA Pharmaceuticals stock or one of its competitors? MarketBeat compares MIRA Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MIRA Pharmaceuticals include Tenaya Therapeutics (TNYA), Corbus Pharmaceuticals (CRBP), Molecular Partners (MOLN), Assertio (ASRT), and Spruce Biosciences (SPRB). These companies are all part of the "pharmaceutical products" industry.

How does MIRA Pharmaceuticals compare to Tenaya Therapeutics?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

Tenaya Therapeutics' return on equity of -80.56% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%
Tenaya Therapeutics	N/A	-80.56%	-65.21%

In the previous week, Tenaya Therapeutics had 2 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 2 mentions for Tenaya Therapeutics and 0 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 0.00 equaled Tenaya Therapeutics'average media sentiment score.

Company	Overall Sentiment
MIRA Pharmaceuticals	Neutral
Tenaya Therapeutics	Neutral

Tenaya Therapeutics is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.47	N/A

Tenaya Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 408.32%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tenaya Therapeutics is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

MIRA Pharmaceuticals has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.83, suggesting that its share price is 183% more volatile than the broader market.

35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are held by institutional investors. 6.7% of MIRA Pharmaceuticals shares are held by company insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Tenaya Therapeutics beats MIRA Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Corbus Pharmaceuticals?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Corbus Pharmaceuticals' return on equity of -70.89% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%

In the previous week, Corbus Pharmaceuticals had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 1 mentions for Corbus Pharmaceuticals and 0 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 0.00 equaled Corbus Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
MIRA Pharmaceuticals	Neutral
Corbus Pharmaceuticals	Neutral

Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A

Corbus Pharmaceuticals has a consensus price target of $40.67, suggesting a potential upside of 339.64%. Given Corbus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

MIRA Pharmaceuticals has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.55, indicating that its stock price is 155% more volatile than the broader market.

35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 6.7% of MIRA Pharmaceuticals shares are held by company insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Corbus Pharmaceuticals beats MIRA Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Molecular Partners?

Molecular Partners (NASDAQ:MOLN) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

26.6% of Molecular Partners shares are owned by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. 5.9% of Molecular Partners shares are owned by company insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

MIRA Pharmaceuticals has lower revenue, but higher earnings than Molecular Partners. Molecular Partners is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$5.65M	28.44	-$74.41M	-$1.94	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A

Molecular Partners has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market.

Molecular Partners' return on equity of -66.62% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-66.62%	-54.85%
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%

In the previous week, Molecular Partners had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 1 mentions for Molecular Partners and 0 mentions for MIRA Pharmaceuticals. Molecular Partners' average media sentiment score of 0.00 equaled MIRA Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Molecular Partners	Neutral
MIRA Pharmaceuticals	Neutral

Molecular Partners presently has a consensus target price of $8.38, suggesting a potential upside of 110.43%. Given Molecular Partners' stronger consensus rating and higher probable upside, research analysts plainly believe Molecular Partners is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Molecular Partners beats MIRA Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Assertio?

Assertio (NASDAQ:ASRT) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

Assertio currently has a consensus price target of $22.65, indicating a potential downside of 3.62%. Given Assertio's higher probable upside, analysts plainly believe Assertio is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Assertio had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 1 mentions for Assertio and 0 mentions for MIRA Pharmaceuticals. Assertio's average media sentiment score of 0.98 beat MIRA Pharmaceuticals' score of 0.00 indicating that Assertio is being referred to more favorably in the media.

Company	Overall Sentiment
Assertio	Positive
MIRA Pharmaceuticals	Neutral

MIRA Pharmaceuticals has a net margin of 0.00% compared to Assertio's net margin of -34.94%. Assertio's return on equity of -38.72% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assertio	-34.94%	-38.72%	-13.32%
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%

49.0% of Assertio shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 5.7% of Assertio shares are held by company insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Assertio has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market.

MIRA Pharmaceuticals has lower revenue, but higher earnings than Assertio. Assertio is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assertio	$118.71M	1.28	-$30.38M	-$5.69	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A

Summary

MIRA Pharmaceuticals beats Assertio on 8 of the 15 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Spruce Biosciences?

Spruce Biosciences (NASDAQ:SPRB) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

In the previous week, Spruce Biosciences had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 1 mentions for Spruce Biosciences and 0 mentions for MIRA Pharmaceuticals. Spruce Biosciences' average media sentiment score of 0.00 equaled MIRA Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Spruce Biosciences	Neutral
MIRA Pharmaceuticals	Neutral

MIRA Pharmaceuticals' return on equity of -140.82% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-155.40%	-101.67%
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%

Spruce Biosciences is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	N/A	N/A	-$38.97M	-$36.60	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A

Spruce Biosciences has a beta of 3.16, indicating that its stock price is 216% more volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

Spruce Biosciences presently has a consensus price target of $163.00, suggesting a potential upside of 210.42%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Spruce Biosciences is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 4.3% of Spruce Biosciences shares are held by insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Spruce Biosciences beats MIRA Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Get MIRA Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MIRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MIRA vs. The Competition

Export

Metric	MIRA Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$39.70M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-0.73	21.61	28.02	24.70
Price / Sales	N/A	340.19	540.37	99.49
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	3.78	8.66	10.96	6.46
Net Income	-$10.44M	$23.81M	$3.57B	$337.01M
7 Day Performance	-6.46%	3.39%	2.12%	1.69%
1 Month Performance	-5.52%	10.81%	5.25%	3.81%
1 Year Performance	-19.59%	62.61%	33.29%	23.90%

MIRA Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MIRA MIRA Pharmaceuticals	0.7106 of 5 stars	$0.94 flat	N/A	-19.6%	$39.70M	N/A	N/A	2
TNYA Tenaya Therapeutics	1.9081 of 5 stars	$0.74 +5.5%	$4.00 +441.8%	+28.8%	$160.21M	N/A	N/A	110	Gap Down
CRBP Corbus Pharmaceuticals	3.0949 of 5 stars	$8.42 +1.3%	$40.67 +383.0%	+21.6%	$156.01M	N/A	N/A	40
MOLN Molecular Partners	2.1447 of 5 stars	$3.84 -2.8%	$8.38 +118.1%	+7.0%	$155.06M	$5.65M	N/A	180	News Coverage High Trading Volume
ASRT Assertio	2.5409 of 5 stars	$23.50 flat	$22.65 -3.6%	N/A	$151.81M	$118.71M	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MIRA) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MIRA Pharmaceuticals (MIRA) Competitors

MIRA vs. TNYA, CRBP, MOLN, ASRT, and SPRB

How does MIRA Pharmaceuticals compare to Tenaya Therapeutics?

Summary

How does MIRA Pharmaceuticals compare to Corbus Pharmaceuticals?

Summary

How does MIRA Pharmaceuticals compare to Molecular Partners?

Summary

How does MIRA Pharmaceuticals compare to Assertio?

Summary

How does MIRA Pharmaceuticals compare to Spruce Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRA vs. The Competition

MIRA Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MIRA Pharmaceuticals (MIRA) Competitors

MIRA vs. TNYA, CRBP, MOLN, ASRT, and SPRB

How does MIRA Pharmaceuticals compare to Tenaya Therapeutics?

Is MIRA or TNYA more profitable?

Does the media prefer MIRA or TNYA?

Which has preferable valuation & earnings, MIRA or TNYA?

Do analysts prefer MIRA or TNYA?

Which has more volatility and risk, MIRA or TNYA?

Do insiders & institutionals hold more shares of MIRA or TNYA?

Summary

How does MIRA Pharmaceuticals compare to Corbus Pharmaceuticals?

Is MIRA or CRBP more profitable?

Does the media refer more to MIRA or CRBP?

Which has preferable earnings and valuation, MIRA or CRBP?

Do analysts prefer MIRA or CRBP?

Which has more risk and volatility, MIRA or CRBP?

Do insiders & institutionals have more ownership in MIRA or CRBP?

Summary

How does MIRA Pharmaceuticals compare to Molecular Partners?

Do institutionals & insiders have more ownership in MOLN or MIRA?

Which has stronger earnings & valuation, MOLN or MIRA?

Which has more volatility & risk, MOLN or MIRA?

Is MOLN or MIRA more profitable?

Does the media favor MOLN or MIRA?

Do analysts prefer MOLN or MIRA?

Summary

How does MIRA Pharmaceuticals compare to Assertio?

Do analysts prefer ASRT or MIRA?

Does the media favor ASRT or MIRA?

Is ASRT or MIRA more profitable?

Do institutionals and insiders hold more shares of ASRT or MIRA?

Which has more volatility and risk, ASRT or MIRA?

Which has better earnings & valuation, ASRT or MIRA?

Summary

How does MIRA Pharmaceuticals compare to Spruce Biosciences?

Does the media prefer SPRB or MIRA?

Is SPRB or MIRA more profitable?

Which has higher valuation and earnings, SPRB or MIRA?

Which has more volatility and risk, SPRB or MIRA?

Do analysts recommend SPRB or MIRA?

Do institutionals & insiders hold more shares of SPRB or MIRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRA vs. The Competition

MIRA Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools